Government “standards“ change quite often depending on who’s paying for them. Now that the pharmaceutical companies no longer have clout in the painkiller space, the standards will change.
More importantly, the GSA is conducting its own trials on Nyloxin and they will make their decision whether to list it or not.
And since we are all admitting that it is a great product, the chances are it will be relisted